<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948168</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-DIAB-01</org_study_id>
    <nct_id>NCT00948168</nct_id>
  </id_info>
  <brief_title>Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes</brief_title>
  <official_title>6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine in type 2 diabetic patients in secondary failure to
      combined oral therapy whether, besides improvement in glycemic control, addition of
      exenatide, a new drug introduced to treat diabetes before addition of insulin to current
      therapy, over 6 months is associated with improvement in beta-cell function, insulin
      sensitivity following 24-hours discontinuation of the drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in HbA1c</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide (Byetta)</intervention_name>
    <description>all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes subjects

          -  40 to 80 years

          -  body mass index (BMI) between 25 and 40 kg/m²

          -  baseline glycated haemoglobin (HbA1c) &gt; 7.0 %, despite a maximally-tolerated combined
             oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin

        Exclusion Criteria:

          -  previous or current use of glitazone

          -  previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine

          -  previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliniques universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <state>Brabant</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <last_update_submitted>July 30, 2009</last_update_submitted>
  <last_update_submitted_qc>July 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2009</last_update_posted>
  <responsible_party>
    <organization>Service d'Endocrinologie et Nutrition, Cliniques universitaires St-Luc, Brussels</organization>
  </responsible_party>
  <keyword>T2DM</keyword>
  <keyword>exenatide</keyword>
  <keyword>HbA1c</keyword>
  <keyword>weight</keyword>
  <keyword>waist circumference</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>beta-cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

